Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs. The company also develops health food ingredients, preservatives, protein preparations, and spices. Nippon considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Kyoto, 601-8550, Japan